Results 1 to 10 of about 30,955 (215)

Ranibizumab e bevacizumab intravítreo no tratamento da neovascularização de coróide extrafoveal da degeneração macular relacionada à idade [PDF]

, 2009
PURPOSE: To investigate the efficacy of vascular endothelial growth factor-specific (VEGF) monoclonal antibodies in the treatment of choroidal neovascularization secondary to age-related macular degeneration (AMD) that does not extend beneath the foveal ...
Amaro, Miguel Hage, Roller, Aaron Brock
core   +3 more sources

Long‐term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate long‐term outcomes of anti‐VEGF therapy for nAMD using the Polish Retinal Therapeutic Program Monitoring Registry. Methods The cohort consisted of 63 840 eyes with nAMD qualified for treatment from 2016 to 2022, with follow‐up through 31 October 2023. Long‐term follow‐up (>5 years) was conducted for 7631 eyes.
Sławomir Teper, Daniel Ledwoń, Adam Sendecki, Patrycja Romaniszyn‐Kania, Aleksandra Tuszy, Julia Nycz, Andrzej W. Mitas, Małgorzata Figurska, Edward Wylęgała, Marek Rękas   +9 more
wiley   +1 more source

Radiation therapy for neovascular age-related macular degeneration

Clinical Ophthalmology, 2011
Robert Petrarca, Timothy L JacksonDepartment of Ophthalmology, King’s College Hospital NHS Foundation Trust, London, UKAbstract: Antivascular endothelial growth factor (anti-VEGF) therapies represent the standard of care for most patients ...
Robert Petrarca, Timothy L Jackson
doaj  

Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis

International Journal of Retina and Vitreous, 2022
Background Aflibercept is a relatively new anti-VEGF used to treat neovascular age-related macular degeneration (AMD). The purpose of this review is to evaluate the effect of pro re nata (PRN) and fixed regimen (bimonthly) of aflibercept injection for ...
Andi Arus Victor, Yan Martha Putri
doaj   +1 more source

'You've got dry macular degeneration, end of story': a qualitative study into the experience of living with non-neovascular age-related macular degeneration. [PDF]

, 2019
BACKGROUND/OBJECTIVES: To investigate the impact of non-neovascular (dry) age-related macular degeneration (AMD) on the person with respect to diagnosis, vision loss and coping strategies.
Binns, A. M., Crabb, D. P., Jones, L., Taylor, D. J.   +3 more
core   +2 more sources

Characterizing and assessing vision‐related quality of life among patients discontinued treatment for neovascular age‐related macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose This study characterized and assessed vision‐related quality of life (VRQoL) in patients with neovascular age‐related macular degeneration (nAMD) who discontinued treatment with intravitreal anti‐vascular endothelial growth factor (anti‐VEGF), comparing them to those undergoing treatment.
Noreddin Shekho, Anna Stage Vergmann, Frederik Nørregaard Pedersen, Lonny Stokholm, Benjamin Sommer Thinggaard   +4 more
wiley   +1 more source

An Evaluation of a Battery of Functional and Structural Tests as Predictors of Likely Risk of Progression of Age-Related Macular Degeneration. [PDF]

, 2018
Purpose: To evaluate the ability of visual function and structural tests to identify the likely risk of progression from early/intermediate to advanced AMD, using the Age-Related Eye Disease Study (AREDS) simplified scale as a surrogate for risk of ...
Bailey, C., Binns, A. M., Margrain, T. H., Robinson, D. G.   +3 more
core   +3 more sources

Non‐physician delivered intravitreal injection service: A systematic review of safety, implementation, training and patient experience

Acta Ophthalmologica, EarlyView.
Abstract The global demand for intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy continues to rise, straining ophthalmic capacity worldwide. Task shifting from physicians to trained non‐physician healthcare professionals has emerged as a potential strategy to expand service delivery.
Trang Truong Laursen, Haris Bralic, Jakob Grauslund, Yousif Subhi, Lonny Stokholm   +4 more
wiley   +1 more source

Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF [PDF]

, 2010
Background Cumulative light exposure is significantly associated with progression of age-related macular degeneration (AMD). Inhibition of vascular endothelial growth factor is the main target of current antiangiogenic treatment strategies in AMD ...
Alge, C. S., Hirneiß, Christoph, Kampik, Anselm, Kernt, Marcus, Liegl, R. G., Neubauer, A. S., Ulbig, Michael W., Wolf, Armin   +7 more
core   +3 more sources

Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4

Acta Ophthalmologica, EarlyView.
Abstract Purpose Assessing the 24‐month treatment outcome of half‐dose photodynamic therapy (PDT) or oral eplerenone in chronic central serous chorioretinopathy (cCSC). Methods Multicentre randomized clinical trial included cCSC patients from the SPECTRA trial who were randomized to receive half‐dose PDT or oral eplerenone.
Helena M. A. Feenstra, Issam El Mansori, Thomas J. van Rijssen, Roula Tsonaka, Roselie M. H. Diederen, Carel B. Hoyng, Reinier O. Schlingemann, Camiel J. F. Boon, Elon H. C. van Dijk   +8 more
wiley   +1 more source